House Committee Approves Drug Price Transparency Legislation/Drug Sample Reporting Requirement Under Sunshine Act

Clearing the way for consideration by the US House of Representatives, the Ways and Means Committee has unanimously approved bipartisan legislation aimed at increasing drug price transparency by manufacturers and pharmacy benefit managers through enhanced reporting and accountability requirements.

Read more detail on Recent Administrative Law posts –

This entry was posted in Administrative law and tagged , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply